CD274 and non-small cell lung carcinoma: <b>Conclusion:</b> Although further prospective and multicenter studies are needed to validate the generalizability of our findings, the clinical implication is that the use of pretreatment SII and/or PD-L1 expression values may predict therapeutic outcomes and assist in optimizing individualized treatment strategies for patients with advanced NSCLC.